JP2023537078A5 - - Google Patents

Info

Publication number
JP2023537078A5
JP2023537078A5 JP2023509418A JP2023509418A JP2023537078A5 JP 2023537078 A5 JP2023537078 A5 JP 2023537078A5 JP 2023509418 A JP2023509418 A JP 2023509418A JP 2023509418 A JP2023509418 A JP 2023509418A JP 2023537078 A5 JP2023537078 A5 JP 2023537078A5
Authority
JP
Japan
Prior art keywords
antibody
seq
amino acid
acid sequence
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023509418A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023537078A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/072203 external-priority patent/WO2022034044A1/en
Publication of JP2023537078A publication Critical patent/JP2023537078A/ja
Publication of JP2023537078A5 publication Critical patent/JP2023537078A5/ja
Pending legal-status Critical Current

Links

JP2023509418A 2020-08-10 2021-08-09 COVID-19を治療及び防止するためのSARS-CoV-2抗体 Pending JP2023537078A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063063862P 2020-08-10 2020-08-10
US63/063,862 2020-08-10
US202063112104P 2020-11-10 2020-11-10
US63/112,104 2020-11-10
PCT/EP2021/072203 WO2022034044A1 (en) 2020-08-10 2021-08-09 Sars-cov-2 antibodies for treatment and prevention of covid-19

Publications (2)

Publication Number Publication Date
JP2023537078A JP2023537078A (ja) 2023-08-30
JP2023537078A5 true JP2023537078A5 (https=) 2024-07-25

Family

ID=77595513

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023509418A Pending JP2023537078A (ja) 2020-08-10 2021-08-09 COVID-19を治療及び防止するためのSARS-CoV-2抗体

Country Status (11)

Country Link
US (2) US20220041694A1 (https=)
EP (1) EP4192860A1 (https=)
JP (1) JP2023537078A (https=)
KR (1) KR20230045613A (https=)
CN (1) CN116234577A (https=)
AU (1) AU2021325339A1 (https=)
BR (1) BR112023002234A2 (https=)
CA (1) CA3190280A1 (https=)
IL (1) IL300257A (https=)
TW (1) TW202221025A (https=)
WO (1) WO2022034044A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20240182T1 (hr) 2020-03-26 2024-04-26 Vanderbilt University Ljudska monoklonska protutijela za teški akutni respiratorni sindrom koronavirusa 2 (sars-cov-2)
TW202342510A (zh) 2022-02-18 2023-11-01 英商Rq生物科技有限公司 抗體
US20250289871A1 (en) 2022-04-29 2025-09-18 Astrazeneca Uk Limited Sars-cov-2 antibodies and methods of using the same

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
EP1229125A4 (en) 1999-10-19 2005-06-01 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING A POLYPEPTIDE
ES2252261T3 (es) 2000-06-28 2006-05-16 Glycofi, Inc. Metodos para producir glicoproteinas modificadas.
CA2424977C (en) 2000-10-06 2008-03-18 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
CA2953239A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kirin Co., Ltd. Antibody composition-producing cell
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
NZ571596A (en) 2001-08-03 2010-11-26 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
CN101613705A (zh) 2002-03-19 2009-12-30 国际植物研究所 在植物中优化聚糖生成
EP2248892B1 (en) 2003-01-22 2015-04-22 Roche Glycart AG Fusion constructs and use of same to produce antibodies with increased FC receptor binding affinity and effector function
BRPI0611445A2 (pt) 2005-05-09 2010-09-08 Glycart Biotechnology Ag molécula de ligação a antìgeno glicomanipulada, polinucleotìdeo, polipeptìdeo, vetor, célula hospedeira, método para produção, uso e composição farmacêutica
JP2009526520A (ja) 2006-01-17 2009-07-23 バイオレックス セラピュティックス インク 植物中でのn−グリカンのヒト化及び最適化のための組成物及び方法
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
US8591886B2 (en) 2007-07-12 2013-11-26 Gitr, Inc. Combination therapies employing GITR binding molecules
CN104119438A (zh) 2009-01-29 2014-10-29 米迪缪尼有限公司 延长体内半衰期的人抗il-6抗体及其在治疗肿瘤、自身免疫性疾病和炎症性疾病中的应用
ES2692268T5 (en) 2011-03-29 2025-02-26 Roche Glycart Ag Antibody fc variants
CA2959571A1 (en) * 2014-09-03 2016-03-10 Medimmune Limited Stable anti-il-4r-alpha antibody formulation
HRP20240182T1 (hr) * 2020-03-26 2024-04-26 Vanderbilt University Ljudska monoklonska protutijela za teški akutni respiratorni sindrom koronavirusa 2 (sars-cov-2)
TW202208423A (zh) * 2020-05-17 2022-03-01 英商阿斯特捷利康英國股份有限公司 Sars-cov-2抗體及其選擇和使用方法

Similar Documents

Publication Publication Date Title
JP2024150751A5 (https=)
KR102757960B1 (ko) 간세포암(hepatocellular carcinoma: HCC)에 대한 면역 치료
JP2015503909A5 (https=)
JP2023537078A5 (https=)
JP2014511179A5 (https=)
JP2019523295A5 (https=)
JP2018529635A5 (https=)
JP2018500014A5 (https=)
RU2015144105A (ru) Антитела к гепсидину и их применения
JP2017535257A5 (https=)
JP2016513664A5 (https=)
JP2021526534A5 (https=)
JP2017536354A5 (https=)
JP2011509245A5 (https=)
JP2019527194A5 (https=)
JP2023540526A5 (https=)
JP2024506315A5 (https=)
JP2013508292A5 (https=)
US20250034272A1 (en) Compositions and methods for treating severe asthma
JP2021511387A5 (https=)
JP2022512647A5 (https=)
JP2021525806A5 (https=)
JPWO2020059847A5 (https=)
JP2022553851A5 (https=)
JP2017529324A5 (https=)